Natural Products Modulating Angiotensin Converting Enzyme 2 (ACE2) as Potential COVID-19 Therapies
The 2019 coronavirus disease (COVID-19) is a potentially fatal multisystemic infection caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Currently, viable therapeutic options that are cost effective, safe and readily available are desired, but lacking. Nevertheless, the pan...
Gespeichert in:
Veröffentlicht in: | Frontiers in pharmacology 2021-05, Vol.12, p.629935, Article 629935 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | |
container_start_page | 629935 |
container_title | Frontiers in pharmacology |
container_volume | 12 |
creator | Abubakar, Murtala Bello Usman, Dawoud El-Saber Batiha, Gaber Cruz-Martins, Natalia Malami, Ibrahim Ibrahim, Kasimu Ghandi Abubakar, Bilyaminu Bello, Muhammad Bashir Muhammad, Aliyu Gan, Siew Hua Dabai, Aliyu Ibrahim Alblihed, M. Ghosh, Arabinda Badr, Reem H. Thangadurai, Devarajan Imam, Mustapha Umar |
description | The 2019 coronavirus disease (COVID-19) is a potentially fatal multisystemic infection caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Currently, viable therapeutic options that are cost effective, safe and readily available are desired, but lacking. Nevertheless, the pandemic is noticeably of lesser burden in African and Asian regions, where the use of traditional herbs predominates, with such relationship warranting a closer look at ethnomedicine. From a molecular viewpoint, the interaction of SARS-CoV-2 with angiotensin converting enzyme 2 (ACE2) is the crucial first phase of COVID-19 pathogenesis. Here, we review plants with medicinal properties which may be implicated in mitigation of viral invasion either via direct or indirect modulation of ACE2 activity to ameliorate COVID-19. Selected ethnomedicinal plants containing bioactive compounds which may prevent and mitigate the fusion and entry of the SARS-CoV-2 by modulating ACE2-associated up and downstream events are highlighted. Through further experimentation, these plants could be supported for ethnobotanical use and the phytomedicinal ligands could be potentially developed into single or combined preventive therapeutics for COVID-19. This will benefit researchers actively looking for solutions from plant bioresources and help lessen the burden of COVID-19 across the globe. |
doi_str_mv | 10.3389/fphar.2021.629935 |
format | Article |
fullrecord | <record><control><sourceid>pubmed_webof</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8126690</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_70c576ae6de24bb98e990d3a87895897</doaj_id><sourcerecordid>34012391</sourcerecordid><originalsourceid>FETCH-LOGICAL-c492t-8aeaed7b569e11065d0d9cd4f26b54bcef7a659c227ef2d14d0cd29728d994c83</originalsourceid><addsrcrecordid>eNqNkU9vEzEQxVcIRKvSD8AF7RGEEvxn1-u5IEVLgEiF9lC4Wl57NnGV2JG9KSqfHm8WovaGL2ON3zxr3q8oXlMy51zCh36_0XHOCKNzwQB4_aw4p0LwGUjKnj-6nxWXKd2RfHiWieplccYrQhkHel503_VwiHpb3sRgD2ZI5bdct3pwfl0u_NqFAX1yvmyDv8d4bC_974cdlqx8u2iX7F2pU3kzygaXfdrrn6tPMwrl7Qaj3jtMr4oXvd4mvPxbL4ofn5e37dfZ1fWXVbu4mpkK2DCTGjXapqsFIKVE1JZYMLbqmejqqjPYN1rUYBhrsGeWVpYYy6Bh0gJURvKLYjX52qDv1D66nY4PKminjo0Q10rnBcwWVUNM3QiNwiKrug4kAhDLtWwk1BKa7PVx8tofuh1ak5fLIT0xffri3Uatw73KeQsBJBvQycDEkFLE_jRLiRr5qSM_NfJTE7888-bxp6eJf7Sy4P0k-IVd6JNx6A2eZBmwqHNwlI2sR7X8f3Xrhsw8-DYc_MD_AG0duCg</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Natural Products Modulating Angiotensin Converting Enzyme 2 (ACE2) as Potential COVID-19 Therapies</title><source>DOAJ Directory of Open Access Journals</source><source>PubMed Central Open Access</source><source>Web of Science - Science Citation Index Expanded - 2021<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /></source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Abubakar, Murtala Bello ; Usman, Dawoud ; El-Saber Batiha, Gaber ; Cruz-Martins, Natalia ; Malami, Ibrahim ; Ibrahim, Kasimu Ghandi ; Abubakar, Bilyaminu ; Bello, Muhammad Bashir ; Muhammad, Aliyu ; Gan, Siew Hua ; Dabai, Aliyu Ibrahim ; Alblihed, M. ; Ghosh, Arabinda ; Badr, Reem H. ; Thangadurai, Devarajan ; Imam, Mustapha Umar</creator><creatorcontrib>Abubakar, Murtala Bello ; Usman, Dawoud ; El-Saber Batiha, Gaber ; Cruz-Martins, Natalia ; Malami, Ibrahim ; Ibrahim, Kasimu Ghandi ; Abubakar, Bilyaminu ; Bello, Muhammad Bashir ; Muhammad, Aliyu ; Gan, Siew Hua ; Dabai, Aliyu Ibrahim ; Alblihed, M. ; Ghosh, Arabinda ; Badr, Reem H. ; Thangadurai, Devarajan ; Imam, Mustapha Umar</creatorcontrib><description>The 2019 coronavirus disease (COVID-19) is a potentially fatal multisystemic infection caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Currently, viable therapeutic options that are cost effective, safe and readily available are desired, but lacking. Nevertheless, the pandemic is noticeably of lesser burden in African and Asian regions, where the use of traditional herbs predominates, with such relationship warranting a closer look at ethnomedicine. From a molecular viewpoint, the interaction of SARS-CoV-2 with angiotensin converting enzyme 2 (ACE2) is the crucial first phase of COVID-19 pathogenesis. Here, we review plants with medicinal properties which may be implicated in mitigation of viral invasion either via direct or indirect modulation of ACE2 activity to ameliorate COVID-19. Selected ethnomedicinal plants containing bioactive compounds which may prevent and mitigate the fusion and entry of the SARS-CoV-2 by modulating ACE2-associated up and downstream events are highlighted. Through further experimentation, these plants could be supported for ethnobotanical use and the phytomedicinal ligands could be potentially developed into single or combined preventive therapeutics for COVID-19. This will benefit researchers actively looking for solutions from plant bioresources and help lessen the burden of COVID-19 across the globe.</description><identifier>ISSN: 1663-9812</identifier><identifier>EISSN: 1663-9812</identifier><identifier>DOI: 10.3389/fphar.2021.629935</identifier><identifier>PMID: 34012391</identifier><language>eng</language><publisher>LAUSANNE: Frontiers Media Sa</publisher><subject>ACE2 ; COVID-19 ; Life Sciences & Biomedicine ; medicinal plants ; Pharmacology ; Pharmacology & Pharmacy ; renin-angiotensin-system ; SARS-CoV-2 ; Science & Technology</subject><ispartof>Frontiers in pharmacology, 2021-05, Vol.12, p.629935, Article 629935</ispartof><rights>Copyright © 2021 Abubakar, Usman, El-Saber Batiha, Cruz-Martins, Malami, Ibrahim, Abubakar, Bello, Muhammad, Gan, Dabai, Alblihed, Ghosh, Badr, Thangadurai and Imam.</rights><rights>Copyright © 2021 Abubakar, Usman, El-Saber Batiha, Cruz-Martins, Malami, Ibrahim, Abubakar, Bello, Muhammad, Gan, Dabai, Alblihed, Ghosh, Badr, Thangadurai and Imam. 2021 Abubakar, Usman, El-Saber Batiha, Cruz-Martins, Malami, Ibrahim, Abubakar, Bello, Muhammad, Gan, Dabai, Alblihed, Ghosh, Badr, Thangadurai and Imam</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>true</woscitedreferencessubscribed><woscitedreferencescount>20</woscitedreferencescount><woscitedreferencesoriginalsourcerecordid>wos000651061200001</woscitedreferencesoriginalsourcerecordid><citedby>FETCH-LOGICAL-c492t-8aeaed7b569e11065d0d9cd4f26b54bcef7a659c227ef2d14d0cd29728d994c83</citedby><cites>FETCH-LOGICAL-c492t-8aeaed7b569e11065d0d9cd4f26b54bcef7a659c227ef2d14d0cd29728d994c83</cites><orcidid>0000-0002-3891-5949 ; 0000-0002-4723-7529 ; 0000-0002-5934-5201 ; 0000-0001-9888-4809</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8126690/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8126690/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,729,782,786,866,887,2104,2116,27931,27932,39265,53798,53800</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34012391$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Abubakar, Murtala Bello</creatorcontrib><creatorcontrib>Usman, Dawoud</creatorcontrib><creatorcontrib>El-Saber Batiha, Gaber</creatorcontrib><creatorcontrib>Cruz-Martins, Natalia</creatorcontrib><creatorcontrib>Malami, Ibrahim</creatorcontrib><creatorcontrib>Ibrahim, Kasimu Ghandi</creatorcontrib><creatorcontrib>Abubakar, Bilyaminu</creatorcontrib><creatorcontrib>Bello, Muhammad Bashir</creatorcontrib><creatorcontrib>Muhammad, Aliyu</creatorcontrib><creatorcontrib>Gan, Siew Hua</creatorcontrib><creatorcontrib>Dabai, Aliyu Ibrahim</creatorcontrib><creatorcontrib>Alblihed, M.</creatorcontrib><creatorcontrib>Ghosh, Arabinda</creatorcontrib><creatorcontrib>Badr, Reem H.</creatorcontrib><creatorcontrib>Thangadurai, Devarajan</creatorcontrib><creatorcontrib>Imam, Mustapha Umar</creatorcontrib><title>Natural Products Modulating Angiotensin Converting Enzyme 2 (ACE2) as Potential COVID-19 Therapies</title><title>Frontiers in pharmacology</title><addtitle>FRONT PHARMACOL</addtitle><addtitle>Front Pharmacol</addtitle><description>The 2019 coronavirus disease (COVID-19) is a potentially fatal multisystemic infection caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Currently, viable therapeutic options that are cost effective, safe and readily available are desired, but lacking. Nevertheless, the pandemic is noticeably of lesser burden in African and Asian regions, where the use of traditional herbs predominates, with such relationship warranting a closer look at ethnomedicine. From a molecular viewpoint, the interaction of SARS-CoV-2 with angiotensin converting enzyme 2 (ACE2) is the crucial first phase of COVID-19 pathogenesis. Here, we review plants with medicinal properties which may be implicated in mitigation of viral invasion either via direct or indirect modulation of ACE2 activity to ameliorate COVID-19. Selected ethnomedicinal plants containing bioactive compounds which may prevent and mitigate the fusion and entry of the SARS-CoV-2 by modulating ACE2-associated up and downstream events are highlighted. Through further experimentation, these plants could be supported for ethnobotanical use and the phytomedicinal ligands could be potentially developed into single or combined preventive therapeutics for COVID-19. This will benefit researchers actively looking for solutions from plant bioresources and help lessen the burden of COVID-19 across the globe.</description><subject>ACE2</subject><subject>COVID-19</subject><subject>Life Sciences & Biomedicine</subject><subject>medicinal plants</subject><subject>Pharmacology</subject><subject>Pharmacology & Pharmacy</subject><subject>renin-angiotensin-system</subject><subject>SARS-CoV-2</subject><subject>Science & Technology</subject><issn>1663-9812</issn><issn>1663-9812</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>HGBXW</sourceid><sourceid>DOA</sourceid><recordid>eNqNkU9vEzEQxVcIRKvSD8AF7RGEEvxn1-u5IEVLgEiF9lC4Wl57NnGV2JG9KSqfHm8WovaGL2ON3zxr3q8oXlMy51zCh36_0XHOCKNzwQB4_aw4p0LwGUjKnj-6nxWXKd2RfHiWieplccYrQhkHel503_VwiHpb3sRgD2ZI5bdct3pwfl0u_NqFAX1yvmyDv8d4bC_974cdlqx8u2iX7F2pU3kzygaXfdrrn6tPMwrl7Qaj3jtMr4oXvd4mvPxbL4ofn5e37dfZ1fWXVbu4mpkK2DCTGjXapqsFIKVE1JZYMLbqmejqqjPYN1rUYBhrsGeWVpYYy6Bh0gJURvKLYjX52qDv1D66nY4PKminjo0Q10rnBcwWVUNM3QiNwiKrug4kAhDLtWwk1BKa7PVx8tofuh1ak5fLIT0xffri3Uatw73KeQsBJBvQycDEkFLE_jRLiRr5qSM_NfJTE7888-bxp6eJf7Sy4P0k-IVd6JNx6A2eZBmwqHNwlI2sR7X8f3Xrhsw8-DYc_MD_AG0duCg</recordid><startdate>20210503</startdate><enddate>20210503</enddate><creator>Abubakar, Murtala Bello</creator><creator>Usman, Dawoud</creator><creator>El-Saber Batiha, Gaber</creator><creator>Cruz-Martins, Natalia</creator><creator>Malami, Ibrahim</creator><creator>Ibrahim, Kasimu Ghandi</creator><creator>Abubakar, Bilyaminu</creator><creator>Bello, Muhammad Bashir</creator><creator>Muhammad, Aliyu</creator><creator>Gan, Siew Hua</creator><creator>Dabai, Aliyu Ibrahim</creator><creator>Alblihed, M.</creator><creator>Ghosh, Arabinda</creator><creator>Badr, Reem H.</creator><creator>Thangadurai, Devarajan</creator><creator>Imam, Mustapha Umar</creator><general>Frontiers Media Sa</general><general>Frontiers Media S.A</general><scope>BLEPL</scope><scope>DTL</scope><scope>HGBXW</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-3891-5949</orcidid><orcidid>https://orcid.org/0000-0002-4723-7529</orcidid><orcidid>https://orcid.org/0000-0002-5934-5201</orcidid><orcidid>https://orcid.org/0000-0001-9888-4809</orcidid></search><sort><creationdate>20210503</creationdate><title>Natural Products Modulating Angiotensin Converting Enzyme 2 (ACE2) as Potential COVID-19 Therapies</title><author>Abubakar, Murtala Bello ; Usman, Dawoud ; El-Saber Batiha, Gaber ; Cruz-Martins, Natalia ; Malami, Ibrahim ; Ibrahim, Kasimu Ghandi ; Abubakar, Bilyaminu ; Bello, Muhammad Bashir ; Muhammad, Aliyu ; Gan, Siew Hua ; Dabai, Aliyu Ibrahim ; Alblihed, M. ; Ghosh, Arabinda ; Badr, Reem H. ; Thangadurai, Devarajan ; Imam, Mustapha Umar</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c492t-8aeaed7b569e11065d0d9cd4f26b54bcef7a659c227ef2d14d0cd29728d994c83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>ACE2</topic><topic>COVID-19</topic><topic>Life Sciences & Biomedicine</topic><topic>medicinal plants</topic><topic>Pharmacology</topic><topic>Pharmacology & Pharmacy</topic><topic>renin-angiotensin-system</topic><topic>SARS-CoV-2</topic><topic>Science & Technology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Abubakar, Murtala Bello</creatorcontrib><creatorcontrib>Usman, Dawoud</creatorcontrib><creatorcontrib>El-Saber Batiha, Gaber</creatorcontrib><creatorcontrib>Cruz-Martins, Natalia</creatorcontrib><creatorcontrib>Malami, Ibrahim</creatorcontrib><creatorcontrib>Ibrahim, Kasimu Ghandi</creatorcontrib><creatorcontrib>Abubakar, Bilyaminu</creatorcontrib><creatorcontrib>Bello, Muhammad Bashir</creatorcontrib><creatorcontrib>Muhammad, Aliyu</creatorcontrib><creatorcontrib>Gan, Siew Hua</creatorcontrib><creatorcontrib>Dabai, Aliyu Ibrahim</creatorcontrib><creatorcontrib>Alblihed, M.</creatorcontrib><creatorcontrib>Ghosh, Arabinda</creatorcontrib><creatorcontrib>Badr, Reem H.</creatorcontrib><creatorcontrib>Thangadurai, Devarajan</creatorcontrib><creatorcontrib>Imam, Mustapha Umar</creatorcontrib><collection>Web of Science Core Collection</collection><collection>Science Citation Index Expanded</collection><collection>Web of Science - Science Citation Index Expanded - 2021</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Frontiers in pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Abubakar, Murtala Bello</au><au>Usman, Dawoud</au><au>El-Saber Batiha, Gaber</au><au>Cruz-Martins, Natalia</au><au>Malami, Ibrahim</au><au>Ibrahim, Kasimu Ghandi</au><au>Abubakar, Bilyaminu</au><au>Bello, Muhammad Bashir</au><au>Muhammad, Aliyu</au><au>Gan, Siew Hua</au><au>Dabai, Aliyu Ibrahim</au><au>Alblihed, M.</au><au>Ghosh, Arabinda</au><au>Badr, Reem H.</au><au>Thangadurai, Devarajan</au><au>Imam, Mustapha Umar</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Natural Products Modulating Angiotensin Converting Enzyme 2 (ACE2) as Potential COVID-19 Therapies</atitle><jtitle>Frontiers in pharmacology</jtitle><stitle>FRONT PHARMACOL</stitle><addtitle>Front Pharmacol</addtitle><date>2021-05-03</date><risdate>2021</risdate><volume>12</volume><spage>629935</spage><pages>629935-</pages><artnum>629935</artnum><issn>1663-9812</issn><eissn>1663-9812</eissn><abstract>The 2019 coronavirus disease (COVID-19) is a potentially fatal multisystemic infection caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Currently, viable therapeutic options that are cost effective, safe and readily available are desired, but lacking. Nevertheless, the pandemic is noticeably of lesser burden in African and Asian regions, where the use of traditional herbs predominates, with such relationship warranting a closer look at ethnomedicine. From a molecular viewpoint, the interaction of SARS-CoV-2 with angiotensin converting enzyme 2 (ACE2) is the crucial first phase of COVID-19 pathogenesis. Here, we review plants with medicinal properties which may be implicated in mitigation of viral invasion either via direct or indirect modulation of ACE2 activity to ameliorate COVID-19. Selected ethnomedicinal plants containing bioactive compounds which may prevent and mitigate the fusion and entry of the SARS-CoV-2 by modulating ACE2-associated up and downstream events are highlighted. Through further experimentation, these plants could be supported for ethnobotanical use and the phytomedicinal ligands could be potentially developed into single or combined preventive therapeutics for COVID-19. This will benefit researchers actively looking for solutions from plant bioresources and help lessen the burden of COVID-19 across the globe.</abstract><cop>LAUSANNE</cop><pub>Frontiers Media Sa</pub><pmid>34012391</pmid><doi>10.3389/fphar.2021.629935</doi><tpages>19</tpages><orcidid>https://orcid.org/0000-0002-3891-5949</orcidid><orcidid>https://orcid.org/0000-0002-4723-7529</orcidid><orcidid>https://orcid.org/0000-0002-5934-5201</orcidid><orcidid>https://orcid.org/0000-0001-9888-4809</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1663-9812 |
ispartof | Frontiers in pharmacology, 2021-05, Vol.12, p.629935, Article 629935 |
issn | 1663-9812 1663-9812 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8126690 |
source | DOAJ Directory of Open Access Journals; PubMed Central Open Access; Web of Science - Science Citation Index Expanded - 2021<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" />; EZB-FREE-00999 freely available EZB journals; PubMed Central |
subjects | ACE2 COVID-19 Life Sciences & Biomedicine medicinal plants Pharmacology Pharmacology & Pharmacy renin-angiotensin-system SARS-CoV-2 Science & Technology |
title | Natural Products Modulating Angiotensin Converting Enzyme 2 (ACE2) as Potential COVID-19 Therapies |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-04T17%3A57%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_webof&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Natural%20Products%20Modulating%20Angiotensin%20Converting%20Enzyme%202%20(ACE2)%20as%20Potential%20COVID-19%20Therapies&rft.jtitle=Frontiers%20in%20pharmacology&rft.au=Abubakar,%20Murtala%20Bello&rft.date=2021-05-03&rft.volume=12&rft.spage=629935&rft.pages=629935-&rft.artnum=629935&rft.issn=1663-9812&rft.eissn=1663-9812&rft_id=info:doi/10.3389/fphar.2021.629935&rft_dat=%3Cpubmed_webof%3E34012391%3C/pubmed_webof%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/34012391&rft_doaj_id=oai_doaj_org_article_70c576ae6de24bb98e990d3a87895897&rfr_iscdi=true |